YourNest Venture Capital Closes a ₹400 Cr Continuation Vehicle

Why It Matters

The fund introduces patient capital to India’s DeepTech sector, improving liquidity for LPs while sustaining growth for high‑potential startups beyond typical fund horizons. This model could reshape exit timing and valuation practices in the domestic venture ecosystem.

Key Takeaways

• YourNest Continuum Fund I closes at ~₹400 cr ($48 M)
• Anchored by HDFC AMC Select FOF I, attracting family offices
• Provides liquidity for LPs, boosting DPI without forced exits
• Targets late‑stage DeepTech startups needing extended patient capital
• YourNest’s prior funds delivered >10× MoIC, underscoring strong track record

Pulse Analysis

Continuation vehicles have emerged as a pragmatic solution for venture firms facing the tension between fixed fund terms and the long gestation periods of deep‑technology startups. By transferring mature portfolio companies into a secondary structure, managers can extend the investment horizon, align incentives with founders, and offer limited partners a clear liquidity path. In India, where fund lifecycles often clash with the multi‑year development cycles of AI, hardware, and biotech ventures, such vehicles are gaining traction as a way to preserve value and avoid premature exits.

YourNest's Continuum Fund I exemplifies this trend, channeling approximately ₹400 crore into a dedicated pool for late‑stage DeepTech assets like Miko, Dozee, and Exponent Energy. The fund’s anchor investor, HDFC AMC Select FOF I, signals confidence from institutional capital in the patient‑capital thesis. YourNest leverages its impressive historical performance—multiple‑on‑invested‑capital (MoIC) exceeding 10× across prior funds—to attract both new and existing LPs seeking higher DPI metrics without sacrificing upside. The vehicle’s design also mitigates the pressure of forced liquidations, allowing portfolio companies to pursue longer‑term scaling strategies.

For the broader venture ecosystem, the rise of continuation funds could recalibrate expectations around exit timing and valuation benchmarks. LPs gain a more predictable return profile, while founders benefit from sustained operational support and reduced exit pressure. As Indian DeepTech ventures continue to attract global interest, the availability of patient capital may become a differentiating factor in securing market leadership. YourNest’s move may prompt peers to adopt similar structures, potentially reshaping capital allocation dynamics across the country’s high‑growth sectors.